Paresh Vishwasrao
Overview
Explore the profile of Paresh Vishwasrao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
51
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ghimire H, Madabushi S, Vercellino J, Brooks J, Zuro D, Lim J, et al.
Front Oncol
. 2024 Oct;
14:1414488.
PMID: 39450249
Background: There is a need for therapies that can mitigate bone marrow dysfunction and organ toxicity that occur following myeloablative injury and reduced intensity conditioning regimens used in patients undergoing...
2.
Boucher J, Shrestha B, Vishwasrao P, Leick M, Cervantes E, Ghafoor T, et al.
Mol Ther Oncolytics
. 2023 Dec;
31:100751.
PMID: 38075241
CD33 and CD123 are expressed on the surface of human acute myeloid leukemia blasts and other noncancerous tissues such as hematopoietic stem cells. On-target off-tumor toxicities may limit chimeric antigen...
3.
Lim J, Madabushi S, Vishwasrao P, Song J, Abdelhamid A, Ghimire H, et al.
Front Oncol
. 2022 Nov;
12:1045016.
PMID: 36439420
Total body irradiation (TBI) is a commonly used conditioning regimen for hematopoietic stem cell transplant (HCT), but dose heterogeneity and long-term organ toxicity pose significant challenges. Total marrow irradiation (TMI),...
4.
Madabushi S, Fouda R, Ghimire H, Abdelhamid A, Lim J, Vishwasrao P, et al.
Front Oncol
. 2022 Sep;
12:969429.
PMID: 36147914
Sickle cell disease (SCD) is a serious global health problem, and currently, the only curative option is hematopoietic stem cell transplant (HCT). However, myeloablative total body irradiation (TBI)-based HCT is...
5.
Vishwasrao P, Li G, Boucher J, Smith D, Hui S
Cancers (Basel)
. 2022 Mar;
14(5).
PMID: 35267549
Engineered T cells expressing chimeric antigen receptors (CARs) on their cell surface can redirect antigen specificity. This ability makes CARs one of the most promising cancer therapeutic agents. CAR-T cells...
6.
Waffarn E, Khosravi-Maharlooei M, Vecchione A, Shao S, Vishwasrao P, Holzl M, et al.
Xenotransplantation
. 2021 Apr;
28(4):e12691.
PMID: 33904221
Background: A major obstacle to the success of organ transplantation from pigs to humans, necessitated by the shortage of human organs, is robust humoral immune rejection by pig-reactive human antibodies....
7.
Kumar B, Orellana M, Brooks J, Madabushi S, Vishwasrao P, Parra L, et al.
Haematologica
. 2020 Oct;
106(5):1484-1488.
PMID: 33054109
No abstract available.
8.
Brooks J, Kumar B, Zuro D, Raybuck J, Madabushi S, Vishwasrao P, et al.
Int J Radiat Oncol Biol Phys
. 2020 Aug;
109(1):60-72.
PMID: 32841681
Purpose: Although vascular alterations in solid tumor malignancies are known to decrease therapeutic delivery, the effects of leukemia-induced bone marrow vasculature (BMV) alterations on therapeutic delivery are not well known....
9.
Srideshikan S, Brooks J, Zuro D, Kumar B, Sanchez J, Parra L, et al.
Clin Cancer Res
. 2019 Sep;
25(24):7463-7474.
PMID: 31548348
Purpose: Acute myeloid leukemia (AML) is a highly aggressive form of leukemia, which results in poor survival outcomes. Currently, diagnosis and prognosis are based on invasive single-point bone marrow biopsies...